

1 **Title Page**

2 **Tripod transcranial alternating current stimulation at 5-Hz to alleviate anxiety**

3 **symptoms: a preliminary report**

4

5 Tien-Wen Lee <sup>a</sup>, Chiang-Shan R. Li <sup>b,c,d</sup>, Gerald Tramontano <sup>a\*</sup>

6

7 <sup>a</sup> The NeuroCognitive Institute (NCI) Clinical Research Foundation, NJ 07856, US

8 <sup>b</sup> Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06520

9 <sup>c</sup> Department of Neuroscience, Yale University School of Medicine, New Haven, CT

10 06520

11 <sup>d</sup> Wu Tsai Institute, Yale University, New Haven, CT 06520

12

13 \* Corresponding author at The NeuroCognitive Institute, New Jersey, US

14 Address: 111 Howard Blvd., Suite 204, Mt. Arlington, NJ 07856

15

16 Web: <http://neuroci.com/>

17 Email: [gtramontano@neuroci.com](mailto:gtramontano@neuroci.com)

18 Tel: 973-601-0100

19 Fax: 973-710-9142

20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Email addresses for the other author:

2 TW Lee: [dwleeibru@gmail.com](mailto:dwleeibru@gmail.com)

3 CSR Li: [chiang-shan.li@yale.edu](mailto:chiang-shan.li@yale.edu)

4

5 **Running Title:** Tripod tACS at 5-Hz may decrease anxiety

6

7 **Keywords:** Frontoparietal network; Limbic system; Transcranial alternating current

8 stimulation (tACS); transcranial electrical stimulation (tES); Neuromodulation

9

10

1 **ABSTRACT**

2 **Introduction** One of the most common applications of transcranial electrical  
3 stimulation (tES) at low current intensity is to induce a relaxed state or reduce anxiety.  
4 With technical advancement, different waveforms, montages, and parameters can be  
5 incorporated into the treatment regimen. We developed a novel protocol to treat  
6 individuals with anxiety disorders by transcranial alternating current stimulation  
7 (tACS).

8 **Methods** A total of 27 individuals with anxiety disorders underwent tACS treatment  
9 for 12 sessions, with each session lasting 25 minutes. tACS at 5 Hz was applied to F4  
10 (1.0 mA), P4 (1.0 mA), and T8 (2.0 mA) EEG lead positions (tripod), with sinewave  
11 oscillation between T8 and F4/P4. We evaluated the primary and secondary  
12 outcomes using the Beck Anxiety Inventory (BAI) and neuropsychological  
13 assessments.

14 **Results** Of the 27 patients, 19 (70.4%) experienced a reduction in symptom severity  
15 greater than 50%, with an average reduction of BAI 58.5%. All reported side effects  
16 were mild, with itching or tingling being the most common complaint. No significant  
17 differences were noted in attention, linguistic working memory, visuospatial working  
18 memory, or long-term memory in neuropsychological assessments.

19 **Conclusion** The results suggest the potential of this novel tripod tACS design as a

1 rapid anxiety alleviator and the importance of a clinical trial to verify its efficacy.

## 1 **Introduction**

2 Developed for more than one century and earlier than electroencephalography (EEG),  
3 transcranial electrical stimulation (tES) refers to various non-invasive techniques for  
4 applying electrical currents to the brain in both research and clinical settings (Bikson  
5 et al., 2019). Anxiety reduction has been one of the earliest and most common uses  
6 of tES, and many commercial setups, such as Electrosleep and Alpha-Stim, are  
7 available for the application of tES (Morriss et al., 2019; Robinovitch, 1914). It was  
8 estimated that 3.8 to 25% of people suffered from anxiety disorders (Remes et al.,  
9 2016), while less than half received treatment. It is acknowledged that tES is a safe  
10 treatment option for many neuropsychiatric conditions (Antal et al., 2017); however,  
11 the evidence for its therapeutic effects seems less than compelling (Kavirajan et al.,  
12 2014; Shekelle et al., 2018). With the recent technological advancement of tES  
13 (Guleyupoglu et al., 2013), we considered here a new protocol to improve the  
14 treatment efficacy further.

15 In Electrosleep, electrical stimulation generally covered the orbital area and  
16 mastoid, the delivered waveforms were pulsed at 30–100 Hz, and the intensity was  
17 set at the level of a few milliamperes (mA). Electrosleep produces a relaxing effect,  
18 which may lead to sleep as an indirect side effect. Electrosleep was thus renamed  
19 Cranial Electrostimulation Therapy (Knutson, 1967), and the nomenclature was

1 updated several times over the ensuing decades (Guleyupoglu et al., 2013).  
2 NeuroTone 101, which adopted alternating current waveforms, was reviewed, and  
3 approved by FDA as the first class-II cranial electrotherapy stimulation (CES) device  
4 for treating anxiety, insomnia, and depression (21 Code of Federal Regulations [CFR]  
5 882.5800, 1978). Over time, more CES devices have been marketed for addressing  
6 anxiety-related issues. Certain second-generation CES devices moved from  
7 transcranial stimulation to applying small square pulsed electric currents through  
8 bilateral ear clips with lower frequencies (e.g., 0.5 Hz) and intensity (e.g., hundreds of  
9 microamperes) (Bystritsky et al., 2008). These are sometimes referred to as  
10 Alpha-Stim because they were believed to improve cortical alpha production, which  
11 could contribute to their effectiveness in reducing anxiety.

12 There are fundamental differences in the designs and stimulation protocols,  
13 including the montage, stimulation frequency, and intensity, between Electrosleep  
14 and Alpha-Stim. New treatment modalities have been introduced to the treatment of  
15 anxiety disorders, including transcranial direct current stimulation (tDCS) and  
16 transcranial alternating current stimulation (tACS) (Clancy et al., 2017; Hampstead et  
17 al., 2016). The intensity typically falls within the range of several mA, and stimulation  
18 sites have been extended to the frontal, parietal, and/or temporal regions to target  
19 the frontoparietal network and limbic system. The frontoparietal network plays a

1 critical role in regulating anxiety, and the limbic system is implicated in the  
2 manifestation of hyperarousal, worry, apprehension, and re-experiencing of negative  
3 emotional states (Engel et al., 2009; Etkin et al., 2006; Hampstead et al., 2016;  
4 Phillips et al., 2008). Among the inter-connected limbic area, the amygdala processes  
5 fear and threat, and its dysfunction represents a central pathophysiological feature of  
6 anxiety (Lee et al., 2013).

7       Although the application of tACS to the treatment of psychiatric conditions is  
8 still in its beginnings, it is of particular interest given that oscillation is a fundamental  
9 nature of neural activities (Lee, 2016), and tACS alters neural rhythmicity through the  
10 imposition of alternating currents (Ali et al., 2013). With the posited mechanisms of  
11 entrainment and cumulative plasticity, tACS may impact the endogenous frequencies  
12 (e.g., delta to gamma) of physiological relevance. Clancy et al. applied alpha  
13 frequency tACS at 2.0 mA to the occipito-parietal sites and observed a rapid  
14 reduction in anxious arousal and aversion to auditory stimuli as well as an  
15 enhancement of posterior alpha power that sustained for several days (Clancy et al.,  
16 2017). The study highlighted the potential of tACS as a treatment option for anxiety  
17 disorders. Alexander et al. applied the alpha tACS over the dorsolateral prefrontal  
18 cortex (dlPFC) in patients with major depressive disorder, with sham and 40 Hz  
19 stimulation as controls (Alexander et al., 2019). The results showed significantly more

1 responders in the 10 Hz-tACS group; however, the alpha power was reduced in the  
2 dlPFC, in contrast to the finding of Clancy et al. (Clancy et al., 2017).

3 Here, we invented a novel tACS protocol and explored its potential in treating  
4 anxiety disorders. In contrast to previous studies, we modulated the frontoparietal  
5 network and limbic system simultaneously through F4, P4, and T8 electrode montage  
6 according to the 10-10 system of EEG convention. The target dosage was set to 2.0  
7 mA, and the modulating frequency at 5 Hz, as with a transcranial magnetic  
8 stimulation study that adopted 5 Hz stimulation for treating comorbid post-traumatic  
9 stress disorder (PTSD) and major depression (Philip et al., 2016). The rationale for  
10 higher current dosage is based on the observation that the susceptibility of neurons  
11 to membrane polarization decreases as the frequency of importing alternating  
12 current increases (Anastassiou et al., 2011; Bland and Sale, 2019). To our knowledge,  
13 this is the first study that applies tACS at 5 Hz and targets large-scale frontal, parietal,  
14 and temporal/limbic regions together in the treatment of anxiety disorders.

15

## 16 **Materials and Methods**

### 17 *Participants*

18 We conducted a retrospective analysis of patient databanks from our clinics, covering  
19 the period between 2018 and 2022. Adult patients with the main diagnoses of



1 generalized anxiety disorder (GAD), social anxiety disorder (SAD), and post-traumatic  
2 stress disorder (PTSD), who scored 17 or higher on the Beck Anxiety Inventory (BAI)  
3 (Beck et al., 1993), were considered. Patients who met any of the following criteria  
4 were excluded: (1) Beck Depression Inventory (BDI) score > 23 (i.e., co-morbid  
5 moderate to high depression) (Beck et al., 1987), (2) co-morbid substance use  
6 disorders, and (3) somatoform disorders (Kroenke, 2007). A total of 27 patients (16.6  
7 to 74.6 years of age) diagnosed through semi-structured interviews according to the  
8 Diagnostic and Statistical Manual of Mental Disorders (DSM-5<sup>®</sup>) were included in the  
9 study (American Psychiatric Association, 2013; First, 2014), who were instructed to  
10 continue their current treatments, such as medications, throughout the tES  
11 treatment without adjustment of dosage.

12 Individuals with epilepsy, skull defects, intracranial electrodes, vascular clips or  
13 shunts in the brain, cardiac pacemakers, or other implanted biomedical devices, as  
14 well as pregnant or lactating conditions, were not eligible for tES in accordance with  
15 safety guidelines (Matsumoto, 2017 #12940; Thair, 2017 #13068). Informed written  
16 consent was obtained for each clinical patient according to a protocol approved by  
17 the Pearl Institutional Review Board (Pearl IRB; <https://www.pearlirb.com/>).

18

19 *Clinical assessments*

1 Before and after treatment, all participants were evaluated by the BAI, BDI, and  
2 Personality Assessment Inventory (Beck et al., 1993; Beck et al., 1987; Morey, 1991).  
3 A neuropsychological battery covering the domains of attention (test of visual  
4 attention; TOVA), linguistic working memory (Letter Fluency), visuospatial working  
5 memory (Design Fluency), and long-term memory (free recall) was administered. The  
6 working memory tasks were selected from the Delis-Kaplan Executive Function  
7 System (D-KEFS) (Delis et al., 2001). Long-term memory was assessed by either  
8 Logical Memory II from Wechsler Memory Scale–Fourth Edition (WMS) or California  
9 Verbal Learning Test (CVLT) (Delis et al., 2000; Drozdick et al., 2018). The four tasks  
10 acted as probes, albeit not thoroughly, to explore the functions of the frontal,  
11 parietal, and temporal regions (Fjell et al., 2019; Gron et al., 2001; Marin et al., 2017).  
12 After the current intensity reached the optimum (i.e., 2.0 mA), participants filled out  
13 a questionnaire about the side effects of tES, including itching/tingling sensation,  
14 burning sensation, discomfort or pain, skin lesion, nausea, dizziness, twitching feeling,  
15 tinnitus, sleepiness, visual phosphenes, seizure, amongst others.

16

### 17 *tACS administration*

18 We used the FDA-approved Starstim-8 (Neuroelectronics, Inc.; [www.neuroelectronics.com](http://www.neuroelectronics.com))  
19 in our clinics. Electric currents were sent to the scalp/brain through electrodes that

1 are connected by wires to a rechargeable battery. Before the electrodes are attached,  
2 the scalp needs to be scrubbed with skin preparation gel. The conductive gel is then  
3 applied to fill the space between the scalp and electrodes. The above procedures  
4 aimed to ensure good contact with the scalp and maintain the impedance level  
5 below 5 k ohms (DaSilva et al., 2011).

6 The montage of electrodes covered the right lateral side of the head at F4, T8,  
7 and P4 positions in terms of the 10-10 EEG convention. The peak current intensity  
8 was 2.0 milliamperes (mA) for T8 and 1.0 mA for F4 and P4. Alternating sinewave  
9 currents oscillated at 5 Hz between T8 and F4/P4. During the neuromodulation  
10 session, participants were asked to practice progressive muscle relaxation training by  
11 watching a standardized video to enhance the treatment effects (Jacobson, 1938).  
12 The setup of tACS is illustrated in Figure 1.

13 To help the patients become accustomed to tES, we adopted a dose escalation  
14 approach in the first three sessions: 1.0 mA for session 1, 1.5 mA for session 2, and  
15 2.0 mA for session 3. The stimulation lasted 25 minutes, with a 1-minute ramp-up  
16 and a 30-second ramp-down phase to reduce skin irritation.

17 Unlike Alpha-Stim, which can be self-administered at home (Morriss et al., 2019),  
18 the Starstim-8 system needs to be operated in clinics. The on-site visits were  
19 scheduled for 12 sessions spanning 3 to 4 weeks. Treatment efficacy was evaluated

1 by an index: post-treatment BAI minus pre-treatment BAI)/pre-treatment BAI.

2 Patients with  $\geq 50\%$  reduction in symptom severity were regarded as treatment

3 responders.

4

5 [Figure 1 around here]

6

## 7 **Results**

8 All participants tolerated the maximum current at 2.0 mA. The demographic

9 information, diagnoses, and side effect profiles are summarized in Table 1. The

10 symptom severity reduction measured by BAI was 58.5% (SD 16.2%), and the

11 percentage of responders was 70.4%.

12 Global attention as indexed by the Attention Composite Score of TOVA, working

13 memory as indexed by the total number of correct items in the two fluency tasks of

14 D-KEFS, and long-term memory as indexed by the number of accurate recollections

15 did not show significant differences pre- and post-tACS (all *P* values  $> 0.05$ ; paired

16 t-tests). The findings are summarized in Table 2.

17 We made a supplementary analysis of five depressive cases whose BDI scores

18 were higher than 23, and the treatment efficacy reflected by BAI reduction was

19 26.8%, concordant with the impression that patients with co-morbid psychiatric

1 conditions are more resistant to treatment.

2

3 **Table 1**

4 Demographic, diagnosis, treatment session, and side effect profile of tACS at 5 Hz.

5

6	<b>Demographic</b>		<b>Side Effects (%)</b>	
7				
8	Age	37.3 (SD 16.1)	Itching/Tingling sensation	44.4
9	Gender (M)	10/27	Burning sensation	11.1
10	GAD	24/27	Discomfort or pain	14.8
11	PTSD	2/27	Skin lesion	0
12	SAD	1/27	Nausea	0
13			Dizziness	0
14			Twitching sensation	11.1
15			Tinnitus	0
16			Sleepiness	11.1
17			Visual phosphenes	3.7
18			Seizure	0
19			Others	3.7
20				

21 Note: The subjective ratings of side effects are all mild.

22

23

1

2 **Table 2**

3 Neuropsychological profile before and after treatment.

4

---

5 <b>Tests</b>	<b>case no.</b>	<b>Before (SD)</b>	<b>After (SD)</b>	<b><i>t val</i></b>	<b><i>P val</i></b>
7 Attention (ACS)	23	-4.04 (6.14)	-2.66 (5.68)	1.72	0.100
8 Letter Fluency	23	31.1 (11.51)	34.2 (9.42)	2.07	0.050
9 Design Fluency	18	27.5 (8.21)	30.6 (11.4)	1.54	0.142
10 Long-term Memory	17	11.5 (6.06)	14.7 (7.40)	1.37	0.180

---

11

12 Paired t-test was performed to evaluate the effect of 5Hz tACS on several neuropsychological  
13 functions.

14

15

[Tables 1 and 2 around here]

16

17 **Discussion**

18 The study retrospectively explored the treatment effects of a novel tACS  
19 design—5 Hz tACS targeting right frontal, parietal, and temporal regions—for  
20 patients with anxiety disorders. The regimen used in this study was within the safety  
21 limit of 4 mA and < 60 minutes per day (Antal et al., 2017). The mean symptom  
22 severity reduction was 58.5%, and 70.4% patients showed a reduction of > 50%. All  
23 reported side effects were mild, and the most frequent complaints were itching or  
24 tingling sensation, which was more prominent at the ramp-up phase and attenuated  
25 substantially after the current reached its steady plateau. The neuropsychological  
26 profile of attention, linguistic working memory, visuospatial working memory, and

1 long-term memory did not show significant differences before and after treatment.  
2 Notably, a substantial portion of the patients reported that they experienced  
3 remarkable anxiety reduction within just one treatment session, consistent with  
4 rapid anxiety relief reported by a previous tACS study (Clancy et al., 2017). Thus,  
5 these preliminary results suggest tripod tES at 5 Hz over the right hemisphere as a  
6 safe and promising anxiolytic treatment option that may serve as a rapid anxiety  
7 alleviator.

8       Of the anxiolytic tES devices currently on the market, Alpha-Stim and similar CES  
9 devices may achieve their efficacy through trigeminal and/or vagus nerve stimulation  
10 (via cutaneous vagal afferents) and modulation of the nucleus tractus solitarius, the  
11 ventral posteromedial nucleus of the thalamus, and their projections to the forebrain,  
12 limbic, and brainstem structures (Adair et al., 2020; Barclay and Barclay, 2014; Butt et  
13 al., 2020; Overcash and Kornhauser, 1999). In contrast, our tripod tES design directly  
14 targets the frontoparietal and limbic systems. The neuromodulation effect of tES was  
15 typically considered confined to the cortical surface. However, recent research has  
16 consistently demonstrated the influences of tES on deep cortical and even  
17 subcortical regions (Bland and Sale, 2019; Esmailpour et al., 2020; Krause et al.,  
18 2019; Liu et al., 2018; Louviot et al., 2021). Deep brain stimulation research  
19 suggested that modulation of the peri-amygdalar region, including the bed nucleus of

1 the stria terminalis, may reduce anxiety (Luyten, 2020). The core network that  
2 supports anxiety is largely subcortical or deep cortical, encompassing the amygdala,  
3 insula, ventromedial PFC, orbitofrontal cortex, hippocampus, ventral region of the  
4 anterior cingulate cortex, thalamus, hypothalamus, periaqueductal gray, and specific  
5 brain stem nuclei (Kolesar et al., 2019), with their downstream projections that  
6 regulate behavioral and autonomic manifestations of fear and anxiety (Walker et al.,  
7 2003). Incorporating T8 in the tripod design might allow for modulation of the limbic  
8 system through the amygdala or the lateral temporal area, which belongs to the  
9 default-mode network that conveys limbic information flow (Lee and Xue, 2018). The  
10 F4 and P4 electrodes may help to enhance frontoparietal network function and  
11 hence the regulation of anxiety (Alexander et al., 2019; Brunyé et al., 2021; Ching et  
12 al., 2022; Kavirajan et al., 2014; Lee et al., 2013; Ochsner et al., 2004; Phillips et al.,  
13 2008). In support, Ironside et al. found that stimulation of dlPFC by tDCS significantly  
14 increased activity in cortical regions associated with attentional control and  
15 simultaneously reduced bilateral amygdala reactivity to threatening stimuli (Ironside  
16 et al., 2019).

17 Our treatment design also has practical advantages. Compared with the studies  
18 of Alpha-Stim, the treatment duration (session number x session duration) in our  
19 treatment was much shorter, but the response rate was comparable. For example, in



1 an earlier Alpha-Stim study, participants received 60 min of daily treatment for six  
2 weeks, and the treatment response was approximately 67% (Bystritsky et al., 2008).  
3 A relatively large, controlled study with a similar design and parameters showed a  
4 treatment efficacy of 54.7% and a response rate of 83% (Barclay and Barclay, 2014).  
5 We considered several factors that may account for the effectiveness of treatment  
6 with a shorter duration in this innovative approach. First, we excluded patients with  
7 BDI higher than 23 and focused on anxiety symptom reduction. Second, the montage  
8 of our electrodes allowed for simultaneously modulating the frontoparietal network  
9 and limbic system. Third, it is well known that electrical current decreases with  
10 traveling distance. Our higher treatment dosage of 2.0 mA may allow the modulation  
11 of deep brain structures more effectively. Together, the preliminary results suggest  
12 the potential of our tripod tACS and the need for a randomized controlled design and  
13 head-to-head statistical comparison of the efficacy with other treatment protocols  
14 and experiments. Although the anxiolytic 5-Hz tripod tES seems promising, it may still  
15 require a longer treatment duration to solidify and maintain the efficacy, like  
16 antidepressant is suggested to continue for several months after symptom  
17 improvement.

18 Anxiety disorders are generally treated with psychotherapy and/or  
19 pharmacotherapy. Complete resolution of symptoms may only be seen in

1 approximately 50% of patients (Ballenger, 1999). tES has been regarded as safe (Antal  
2 et al., 2017), and hence an ideal adjunct option to potentiate the therapeutic effects  
3 of extant treatments. Although emotion processing used to be regarded as mediated  
4 by the right hemisphere (Kotz et al., 2006), lateralization is relative, not absolute,  
5 especially for anxiety disorders (Gordon et al., 2010). For anxiety patients who do not  
6 respond adequately to the right-side 5Hz tripod tES, it may be worthwhile to apply  
7 that to the left hemisphere or improvise an alternating left and right treatment  
8 sequence to boost the treatment response. It must be cautious that concurrent T7  
9 and T8 tACS might enhance the bi-hemispheric limbic interaction and worsen the  
10 psychiatric conditions. Nevertheless, our unreported cases showed that anti-phase  
11 tACS over T7 and T8 simultaneously could reduce limbic crosstalk and is another  
12 potential anxiolytic design. Like the trend of “combo” in psychopharmacology for  
13 refractory cases, a combination of different variants of 5Hz tACS may be worthy of  
14 consideration as a potentiation strategy for non-invasive neuromodulation protocol.

15 In particular, less than half of those suffering from anxiety disorders are  
16 estimated to receive treatment (Alonso et al., 2018). Home-based tES devices are  
17 now more accessible and user-friendly than ever. With clinicians able to adjust the  
18 parameters remotely, this technology becoming highly feasible for more patients and  
19 a broader range of social scenarios (e.g., in a pandemic when medical service is

1 severely compromised).

2

### 3 **Conclusion**

4 Despite the vast and high enthusiasm for tES, only a few studies have explored the  
5 therapeutic effects of tACS for anxiety. Based on the understanding of brain network  
6 dysfunction in the pathophysiology of anxiety disorders, we developed a tripod 5 Hz  
7 tACS protocol and demonstrated its rapid effects on reducing anxiety symptom  
8 severity. The side effects were minimal. Double-blind and sham-controlled research is  
9 warranted to verify its efficacy and role as an adjunct treatment for anxiety disorders.

10

1 **Authors Contributions**

2 All authors contributed intellectually to this work. TW Lee carried out the analysis  
3 and wrote the first draft. All authors revised and approved the final version of the  
4 manuscript.

5

6 **Acknowledgments**

7 This work was supported by NeuroCognitive Institute (NCI) and NCI Clinical Research  
8 Foundation Inc. We would like to thank Almeida Sergio for helping prepare the  
9 research material.

10

11 **Financial support**

12 N/A.

13

14 **Statements and Declarations**

15 All authors declare no conflicts of interest.

16

17 **Compliance with ethical standards**

18 This research analyzed the databank collected from 2018 to 2022. The authors assert  
19 that all procedures contributing to this work comply with the ethical standards of the

1 relevant national and institutional committees on human experimentation and with

2 the Helsinki Declaration of 1975, as revised in 2008.

3

## 1   **References**

- 2   Adair, D., Truong, D., Esmailpour, Z., Gebodh, N., Borges, H., Ho, L., Douglas Bremner,  
3   J., Badran, B.W., Napadow, V., Clark, V.P., Bikson, M., 2020. Electrical stimulation of  
4   cranial nerves in cognition and disease. *Brain Stimul* 13, 717-750.
- 5   Alexander, M.L., Alagapan, S., Lugo, C.E., Mellin, J.M., Lustenberger, C., Rubinow, D.R.,  
6   Fröhlich, F., 2019. Double-blind, randomized pilot clinical trial targeting alpha  
7   oscillations with transcranial alternating current stimulation (tACS) for the treatment  
8   of major depressive disorder (MDD). *Transl Psychiatry* 9, 106.
- 9   Ali, M.M., Sellers, K.K., Frohlich, F., 2013. Transcranial alternating current stimulation  
10   modulates large-scale cortical network activity by network resonance. *J Neurosci* 33,  
11   11262-11275.
- 12   Alonso, J., Liu, Z., Evans-Lacko, S., Sadikova, E., Sampson, N., Chatterji, S., Abdulmalik,  
13   J., Aguilar-Gaxiola, S., Al-Hamzawi, A., Andrade, L.H., Bruffaerts, R., Cardoso, G., Cia,  
14   A., Florescu, S., de Girolamo, G., Gureje, O., Haro, J.M., He, Y., de Jonge, P., Karam,  
15   E.G., Kawakami, N., Kovess-Masfety, V., Lee, S., Levinson, D., Medina-Mora, M.E.,  
16   Navarro-Mateu, F., Pennell, B.E., Piazza, M., Posada-Villa, J., Ten Have, M., Zarkov, Z.,  
17   Kessler, R.C., Thornicroft, G., 2018. Treatment gap for anxiety disorders is global:  
18   Results of the World Mental Health Surveys in 21 countries. *Depress. Anxiety* 35,  
19   195-208.
- 20   American Psychiatric Association, 2013. Diagnostic and statistical manual of mental  
21   disorders (DSM-5®). American Psychiatric Pub.
- 22   Anastassiou, C.A., Perin, R., Markram, H., Koch, C., 2011. Ephaptic coupling of cortical  
23   neurons. *Nature neuroscience* 14, 217-223.
- 24   Antal, A., Alekseichuk, I., Bikson, M., Brockmoller, J., Brunoni, A.R., Chen, R., Cohen,  
25   L.G., Douthwaite, G., Ellrich, J., Floel, A., Fregni, F., George, M.S., Hamilton, R.,  
26   Hauelsen, J., Herrmann, C.S., Hummel, F.C., Lefaucheur, J.P., Liebetanz, D., Loo, C.K.,  
27   McCaig, C.D., Miniussi, C., Miranda, P.C., Moliadze, V., Nitsche, M.A., Nowak, R.,  
28   Padberg, F., Pascual-Leone, A., Poppendieck, W., Priori, A., Rossi, S., Rossini, P.M.,  
29   Rothwell, J., Rueger, M.A., Ruffini, G., Schellhorn, K., Siebner, H.R., Ugawa, Y., Wexler,  
30   A., Ziemann, U., Hallett, M., Paulus, W., 2017. Low intensity transcranial electric  
31   stimulation: Safety, ethical, legal regulatory and application guidelines. *Clin*  
32   *Neurophysiol* 128, 1774-1809.
- 33   Ballenger, J.C., 1999. Current treatments of the anxiety disorders in adults. *Biol.*  
34   *Psychiatry* 46, 1579-1594.
- 35   Barclay, T.H., Barclay, R.D., 2014. A clinical trial of cranial electrotherapy stimulation  
36   for anxiety and comorbid depression. *J Affect Disord* 164, 171-177.

- 1 Beck, A.T., Epstein, N., Brown, G., Steer, R., 1993. Beck anxiety inventory. *Journal of*  
2 *consulting and clinical psychology*.
- 3 Beck, A.T., Steer, R.A., Brown, G.K., 1987. Beck depression inventory. Harcourt Brace  
4 Jovanovich New York:.
- 5 Bikson, M., Esmaeilpour, Z., Adair, D., Kronberg, G., Tyler, W.J., Antal, A., Datta, A.,  
6 Sabel, B.A., Nitsche, M.A., Loo, C., Edwards, D., Ekhtiari, H., Knotkova, H., Woods, A.J.,  
7 Hampstead, B.M., Badran, B.W., Peterchev, A.V., 2019. Transcranial electrical  
8 stimulation nomenclature. *Brain Stimul* 12, 1349-1366.
- 9 Bland, N.S., Sale, M.V., 2019. Current challenges: the ups and downs of tACS. *Exp*  
10 *Brain Res* 237, 3071-3088.
- 11 Brunyé, T.T., Patterson, J.E., Wooten, T., Hussey, E.K., 2021. A Critical Review of Cranial  
12 Electrotherapy Stimulation for Neuromodulation in Clinical and Non-clinical Samples.  
13 *Frontiers in Human Neuroscience* 15, 12.
- 14 Butt, M.F., Albusoda, A., Farmer, A.D., Aziz, Q., 2020. The anatomical basis for  
15 transcutaneous auricular vagus nerve stimulation. *J Anat* 236, 588-611.
- 16 Bystritsky, A., Kerwin, L., Feusner, J., 2008. A pilot study of cranial electrotherapy  
17 stimulation for generalized anxiety disorder. *J Clin Psychiatry* 69, 412-417.
- 18 Ching, P.Y., Hsu, T.W., Chen, G.W., Pan, C.C., Chu, C.S., Chou, P.H., 2022. Efficacy and  
19 Tolerability of Cranial Electrotherapy Stimulation in the Treatment of Anxiety: A  
20 Systemic Review and Meta-Analysis. *Front Psychiatry* 13, 899040.
- 21 Clancy, K.J., Baisley, S.K., Albizu, A., Kartvelishvili, N., Ding, M., Li, W., 2017.  
22 Transcranial alternating current stimulation induces long-term augmentation of  
23 neural connectivity and sustained anxiety reduction. *bioRxiv*, 204222.
- 24 DaSilva, A.F., Volz, M.S., Bikson, M., Fregni, F., 2011. Electrode positioning and  
25 montage in transcranial direct current stimulation. *J Vis Exp*.
- 26 Delis, D.C., Kaplan, E., Kramer, J.H., 2001. Delis-Kaplan executive function system.  
27 *Assessment*.
- 28 Delis, D.C., Kramer, J.H., Kaplan, E., Ober, B.A., 2000. California verbal learning test.  
29 *Assessment*.
- 30 Drozdick, L.W., Raiford, S.E., Wahlstrom, D., Weiss, L.G., 2018. The Wechsler Adult  
31 Intelligence Scale—Fourth Edition and the Wechsler Memory Scale—Fourth Edition.
- 32 Engel, K., Bandelow, B., Gruber, O., Wedekind, D., 2009. Neuroimaging in anxiety  
33 disorders. *Journal of neural transmission (Vienna, Austria : 1996)* 116, 703-716.
- 34 Esmaeilpour, Z., Kronberg, G., Reato, D., Parra, L.C., Bikson, M., 2020. Temporal  
35 interference stimulation targets deep brain regions by modulating neural oscillations.  
36 *Brain Stimul* 14, 55-65.

- 1 Etkin, A., Egner, T., Peraza, D.M., Kandel, E.R., Hirsch, J., 2006. Resolving emotional  
2 conflict: a role for the rostral anterior cingulate cortex in modulating activity in the  
3 amygdala. *Neuron* 51, 871-882.
- 4 First, M.B., 2014. Structured clinical interview for the DSM (SCID). *The encyclopedia*  
5 *of clinical psychology*, 1-6.
- 6 Fjell, A.M., Sneve, M.H., Sederevicius, D., Sorensen, O., Krogsrud, S.K., Mowinckel,  
7 A.M., Walhovd, K.B., 2019. Volumetric and microstructural regional changes of the  
8 hippocampus underlying development of recall performance after extended  
9 retention intervals. *Developmental cognitive neuroscience* 40, 100723.
- 10 Gordon, E., Palmer, D.M., Cooper, N., 2010. Eeg alpha asymmetry in schizophrenia,  
11 depression, ptsd, panic disorder, adhd and conduct disorder. *Clin. EEG Neurosci.* 41,  
12 178-183.
- 13 Gron, G., Bittner, D., Schmitz, B., Wunderlich, A.P., Tomczak, R., Riepe, M.W., 2001.  
14 Hippocampal activations during repetitive learning and recall of geometric patterns.  
15 *Learn Mem* 8, 336-345.
- 16 Guleyupoglu, B., Schestatsky, P., Edwards, D., Fregni, F., Bikson, M., 2013.  
17 Classification of methods in transcranial electrical stimulation (tES) and evolving  
18 strategy from historical approaches to contemporary innovations. *J Neurosci*  
19 *Methods* 219, 297-311.
- 20 Hampstead, B.M., Briceno, E.M., Mascaro, N., Mourdoukoutas, A., Bikson, M., 2016.  
21 Current Status of Transcranial Direct Current Stimulation in Posttraumatic Stress and  
22 Other Anxiety Disorders. *Curr Behav Neurosci Rep* 3, 95-101.
- 23 Ironside, M., Browning, M., Ansari, T.L., Harvey, C.J., Sekyi-Djan, M.N., Bishop, S.J.,  
24 Harmer, C.J., O'Shea, J., 2019. Effect of Prefrontal Cortex Stimulation on Regulation of  
25 Amygdala Response to Threat in Individuals With Trait Anxiety: A Randomized Clinical  
26 Trial. *JAMA Psychiatry* 76, 71-78.
- 27 Jacobson, E., 1938. Progressive relaxation. *The Journal of Experimental Psychology* 22,  
28 125-133.
- 29 Kavirajan, H.C., Lueck, K., Chuang, K., 2014. Alternating current cranial electrotherapy  
30 stimulation (CES) for depression. *Cochrane Database of Systematic Reviews*.
- 31 Knutson, R.C., 1967. First international symposium on electrosleep therapy and  
32 electroanesthesia: a report. *Anesthesia & Analgesia* 46, 333-339.
- 33 Kolesar, T.A., Bilevicius, E., Wilson, A.D., Kornelsen, J., 2019. Systematic review and  
34 meta-analyses of neural structural and functional differences in generalized anxiety  
35 disorder and healthy controls using magnetic resonance imaging. *Neuroimage Clin* 24,  
36 102016.



- 1 Kotz, S.A., Meyer, M., Paulmann, S., 2006. Lateralization of emotional prosody in the  
2 brain: an overview and synopsis on the impact of study design. *Prog. Brain Res.* 156,  
3 285-294.
- 4 Krause, M.R., Vieira, P.G., Csorba, B.A., Pilly, P.K., Pack, C.C., 2019. Transcranial  
5 alternating current stimulation entrains single-neuron activity in the primate brain.  
6 *Proc Natl Acad Sci U S A* 116, 5747-5755.
- 7 Kroenke, K., 2007. Efficacy of treatment for somatoform disorders: a review of  
8 randomized controlled trials. *Psychosom. Med.* 69, 881-888.
- 9 Lee, T.-W., 2016. Network balance and its relevance to affective disorders: Dialectic  
10 neuroscience. *Pronoun*.
- 11 Lee, T.W., Liu, H.L., Wai, Y.Y., Ko, H.J., Lee, S.H., 2013. Abnormal neural activity in  
12 partially remitted late-onset depression: An fmri study of one-back working memory  
13 task. *Psychiatry Res.* 213, 133-141.
- 14 Lee, T.W., Xue, S.W., 2018. Functional connectivity maps based on hippocampal and  
15 thalamic dynamics may account for the default-mode network. *Eur. J. Neurosci.* 47,  
16 388-398.
- 17 Liu, A., Voroslakos, M., Kronberg, G., Henin, S., Krause, M.R., Huang, Y., Opitz, A.,  
18 Mehta, A., Pack, C.C., Krekelberg, B., Berenyi, A., Parra, L.C., Melloni, L., Devinsky, O.,  
19 Buzsaki, G., 2018. Immediate neurophysiological effects of transcranial electrical  
20 stimulation. *Nat Commun* 9, 5092.
- 21 Louviot, S., Tyvaert, L., Maillard, L.G., Colnat-Coulbois, S., Dmochowski, J., Koessler, L.,  
22 2021. Transcranial Electrical Stimulation generates electric fields in deep human brain  
23 structures. *Brain Stimulation*.
- 24 Luyten, L., 2020. The Bed Nucleus of the Stria Terminalis: Translational Deep Brain  
25 Stimulation to Reduce Anxiety. *Neuroscientist* 26, 278-284.
- 26 Marin, D., Madotto, E., Fabbro, F., Skrap, M., Tomasino, B., 2017. Design fluency and  
27 neuroanatomical correlates in 54 neurosurgical patients with lesions to the right  
28 hemisphere. *J Neurooncol* 135, 141-150.
- 29 Morey, L.C., 1991. Personality assessment inventory. *Psychological Assessment*  
30 *Resources* Odessa, FL.
- 31 Morriss, R., Xydopoulos, G., Craven, M., Price, L., Fordham, R., 2019. Clinical  
32 effectiveness and cost minimisation model of Alpha-Stim cranial electrotherapy  
33 stimulation in treatment seeking patients with moderate to severe generalised  
34 anxiety disorder. *J Affect Disord* 253, 426-437.
- 35 Ochsner, K.N., Ray, R.D., Cooper, J.C., Robertson, E.R., Chopra, S., Gabrieli, J.D., Gross,  
36 J.J., 2004. For better or for worse: Neural systems supporting the cognitive down-  
37 and up-regulation of negative emotion. *Neuroimage* 23, 483-499.

1 Overcash, S.J., Kornhauser, S., 1999. Cranial electrotherapy stimulation in patients  
2 suffering from acute anxiety disorders. *MEDICAL ELECTRONICS-PITTSBURG-* 30,  
3 49-52.

4 Philip, N.S., Ridout, S.J., Albright, S.E., Sanchez, G., Carpenter, L.L., 2016. 5-Hz  
5 Transcranial Magnetic Stimulation for Comorbid Posttraumatic Stress Disorder and  
6 Major Depression. *J Trauma Stress* 29, 93-96.

7 Phillips, M.L., Ladouceur, C.D., Drevets, W.C., 2008. A neural model of voluntary and  
8 automatic emotion regulation: Implications for understanding the pathophysiology  
9 and neurodevelopment of bipolar disorder. *Mol. Psychiatry* 13, 833-857.

10 Remes, O., Brayne, C., Van Der Linde, R., Lafortune, L., 2016. A systematic review of  
11 reviews on the prevalence of anxiety disorders in adult populations. *Brain and*  
12 *behavior* 6, e00497.

13 Robinovitch, L., 1914. Electrical analgesia, sleep and resuscitation. *Anesthesia*. New  
14 York: Appleton, 478.

15 Shekelle, P.G., Cook, I.A., Mlake-Lye, I.M., Booth, M.S., Beroes, J.M., Mak, S., 2018.  
16 Benefits and Harms of Cranial Electrical Stimulation for Chronic Painful Conditions,  
17 Depression, Anxiety, and Insomnia: A Systematic Review. *Ann Intern Med* 168,  
18 414-421.

19 Walker, D.L., Toufexis, D.J., Davis, M., 2003. Role of the bed nucleus of the stria  
20 terminalis versus the amygdala in fear, stress, and anxiety. *Eur. J. Pharmacol.* 463,  
21 199-216.

22

23

24

1 **Figure Legends**

- 2 Fig. 1. An illustration of the neuromodulation setup. Three electrode positions were
- 3 wire-connected to a rechargeable battery: F4, P4, and T8.